Skip to main content
  • Tweet
  • Share on Facebook
  • Share on Google +1
  • Share via Email
  • Contact
  • Glossary
  • Subscribe
  • Search

PATH's Malaria Vaccine Initiative

Accelerating Malaria Vaccine Development

  • About us
    • Our leadership team
    • Donors
    • Contact us
  • Malaria and vaccines
    • Need for a vaccine
    • RTS,S
    • Malaria vaccine roadmap
    • Next-generation vaccines
      • Preventing transmission
      • Preventing infection
    • Vaccine development
      • Our research and development strategy
      • Life cycle of the malaria parasite
      • Preferred product characteristics
    • Evaluation technologies
    • Access
      • Global policy and regulatory pathways
        • Regulatory decisions and prequalifications
        • Policy
      • Preparing for malaria vaccine decisions
        • The decision-making framework tool for malaria vaccines
        • Decision-making framework
          • Economic analysis
          • Public health impact analysis
          • Sociocultural research
      • Financing
        • Gavi, the Vaccine Alliance
        • Other fincancing mechanisms
  • Projects
    • Search vaccine projects
    • Evaluation technology projects
    • MVI Portfolio
    • Past projects
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Presentations
    • Videos
    • Reports
  • News and events
    • Press releases
    • Perspectives
    • Malaria vaccine news
    • Events
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Past advocacy fellows
      • Tools for advocates
    • Propose a project
  • About us
    • Our leadership team
    • Donors
    • Contact us
  • Malaria and vaccines
    • Need for a vaccine
    • RTS,S
    • Malaria vaccine roadmap
    • Next-generation vaccines
      • Preventing transmission
      • Preventing infection
    • Vaccine development
      • Our research and development strategy
      • Life cycle of the malaria parasite
      • Preferred product characteristics
    • Evaluation technologies
    • Access
      • Global policy and regulatory pathways
      • Preparing for malaria vaccine decisions
      • Financing
  • Projects
    • Search vaccine projects
    • Evaluation technology projects
    • MVI Portfolio
    • Past projects
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Presentations
    • Videos
    • Reports
  • News and events
    • Press releases
    • Perspectives
    • Malaria vaccine news
    • Events
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Past advocacy fellows
      • Tools for advocates
    • Propose a project
  • Home
  • News and events
  • Press releases

Press releases

  • Milestone study identifies immune markers that may help predict success of vaccination with RTS,S/AS01 malaria vaccine

    22 Jul 2020
  • PATH receives new five-year contract from USAID for malaria vaccine research and development

    7 Jul 2020
  • PATH continues exciting partnership with the GHIT Fund to develop a next-generation malaria vaccine

    3 Apr 2020
  • PATH and partners receive award for development of world’s first malaria vaccine

    14 Nov 2019
  • Kenya joins Malawi and Ghana to roll out the world’s first malaria vaccine

    13 Sep 2019
  • PATH congratulates Malawi on introducing the first malaria vaccine for African children

    23 Apr 2019
  • New report finds $100 million shortfall in annual global investments in malaria research and development

    19 Jun 2018
  • A Structural Clue to Attacking Malaria’s ‘Achilles Heel’

    15 Nov 2017
  • PATH and Walter Reed Army Institute of Research announce largest-ever controlled malaria infection study

    8 Sep 2017
  • PATH partners with the Mahidol Oxford Tropical Medicine Research Unit on first study of the RTS,S malaria vaccine in Asia

    9 Aug 2017
  • Radboud University Medical Center, the Instituto de Medicina Molecular, and PATH’s Malaria Vaccine Initiative will collaborate on first-in-human study of a novel malaria vaccine approach

    30 May 2017
  • PATH and GSK welcome progress toward RTS,S malaria vaccine pilot implementation with selection of countries

    24 Apr 2017

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • next ›
  • last »

PATH Washington DC

455 Massachusetts Avenue NW, Suite 1000

Washington, DC 20001 | USA 

Tel: 202.822.0033

Fax: 202.457.1466

Email: mvi_info [at] path.org

PATH Headquarters

2201 Westlake Avenue, Suite 200

Seattle, WA 98121 | USA 

Tel: 206.285.3500

Fax: 206.285.6619

Email: info [at] path.org

Website: www.path.org

Follow us

Mail
Twitter
  • Privacy policy
  • Copyright policy
  • Terms of use
© 2021 PATH
Website by Manta Ray Media